- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 26.06. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 26.06. | Reviva Dives on Stock Offering | 2 | Baystreet.ca | ||
| 26.06. | Reviva Pharmaceuticals holdings announces pricing of $10M public offering | 2 | Seeking Alpha | ||
| 26.06. | Reviva preist öffentliches Angebot von 10 Millionen US-Dollar zu 0,50 US-Dollar pro Aktie | 2 | Investing.com Deutsch | ||
| 26.06. | Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 25.06. | Reviva Pharmaceuticals-Aktie fällt nach Ankündigung eines öffentlichen Angebots | 11 | Investing.com Deutsch | ||
| 25.06. | Reviva Pharmaceuticals announces public offering of common stock | 1 | Investing.com | ||
| 25.06. | Reviva Pharmaceuticals stock falls after announcing public offering | 1 | Investing.com | ||
| 25.06. | Reviva Pharmaceuticals announces public offering; shares down nearly 15% | 1 | Seeking Alpha | ||
| 25.06. | Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering | 1 | GlobeNewswire (USA) | ||
| 06.06. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 02.06. | Reviva reports positive year-long schizophrenia drug study | 3 | Investing.com | ||
| 02.06. | Reviva Pharmaceuticals: Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia | 265 | GlobeNewswire (Europe) | - Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms - - Generally well-tolerated with low rates of adverse events and discontinuation... ► Artikel lesen | |
| 30.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.05. | Benchmark hält 14 US-Dollar Kursziel für Reviva Pharmaceuticals-Aktie aufrecht | 3 | Investing.com Deutsch | ||
| 20.05. | Reviva stock target cut to $3 on cash concerns, retains Buy rating | 5 | Investing.com | ||
| 15.05. | Reviva Pharmaceuticals GAAP EPS of -$0.13 | 8 | Seeking Alpha | ||
| 15.05. | Reviva Pharmaceuticals: Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights | 164 | GlobeNewswire (Europe) | - 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment - - Full data set from RECOVER OLE... ► Artikel lesen | |
| 09.04. | Reviva Pharmaceuticals target cut to $14 by Benchmark | 2 | Investing.com | ||
| 03.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 29,125 | +2,28 % | Zäsur im deutschen Gesundheitswesen! Wagen wir bald mehr USA? PanGenomic Health, Bayer, Nestlé | Gibt es US-amerikanische Verhältnisse bald auch in Deutschland? Gesundheitsökonom Jürgen Wasem fordert mehr Selbstbeteiligung von Patienten. Bestimmte Medikamente könnten von der Verschreibungspflicht... ► Artikel lesen | |
| PFIZER | 21,595 | +0,12 % | Pfizer Completes Licensing Agreement With 3SBio For Cancer Drug | NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) Thursday said it has completed the licensing agreement with 3SBio, Inc. for exclusive rights to develop and sell 3SBio's SSGJ-707.As per the deal... ► Artikel lesen | |
| ROCHE | 280,60 | +0,11 % | Roche: Doppelter Rückschlag | Doppelter Dämpfer für den Pharma-Riesen Roche. Für das Krebsmittel Columvi hat die US-Zulassungsbehörde FDA erneut einen negativen Entscheid gefällt. Darüber hinaus muss das Schweizer Unternehmen einen... ► Artikel lesen | |
| VIATRIS | 7,950 | +0,03 % | Why Is Viatris Stock Falling In Pre-market? | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% ophthalmic ointment... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 5,025 | -0,79 % | Cannabis Operator Green Thumb Down 30% YTD: Time to Buy, Sell or Hold? | ||
| CASSAVA SCIENCES | 2,186 | +1,82 % | Cassava Sciences, Inc.: Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development | AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing novel, investigational... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 7,430 | -0,80 % | Edison Group: Edison Issues Report on Newron Pharmaceuticals (NWRN) | London, United Kingdom--(Newsfile Corp. - July 9, 2025) - Edison issues report on Newron Pharmaceuticals (SIX: NWRN).Newron Pharmaceuticals is making significant headway in progressing its drug candidate... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 1,901 | +4,86 % | ORAMED PHARMACEUTICALS INC. - 8-K, Current Report | ||
| ACHIEVE LIFE SCIENCES | 2,370 | +3,49 % | Achieve Life Sciences: Trading-Chance bei Anti-Raucher-Aktie | SD-Leser kennen die Aktie von Achieve Life Sciences von früheren Höhenflügen noch gut. Immer wieder konnten wir uns gezielt Trading-Dynamiken zunutze machen und teils dreistellige Gewinne einfahren.... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 7,610 | -1,27 % | Leerink Partners bekräftigt Outperform-Rating für Aurinia-Aktie nach Studiendaten | ||
| KAZIA THERAPEUTICS | 10,300 | +0,24 % | Kazia Therapeutics Limited: Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase ... | SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial... ► Artikel lesen | |
| LIPOCINE | 3,350 | 0,00 % | Lipocine Inc.: Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression | Phase 3 Top Line Results Expected Q2 2026
SALT LAKE CITY, June 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,100 | 0,00 % | Allergy Therapeutics shares slump as expects to post revenue decline | ||
| LYRA THERAPEUTICS | 8,190 | 0,00 % | Lyra Therapeutics registers shares for resale from warrant exercises | ||
| SUNSHINE BIOPHARMA | 1,560 | -1,27 % | Sunshine Biopharma Inc.: Sunshine Biopharma Launches NIOPEG Into $10 Billion Biologics Market | FORT LAUDERDALE, FL / ACCESS Newswire / July 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of... ► Artikel lesen |
Das Unternehmen REVIVA PHARMACEUTICALS HOLDINGS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,431 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.